Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1890147 | 0.98 | HRH3 (0.41) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL18868171 | 0.84 | MKNK1 (0.49) | HRH3NPC1RAB9ASMN1; SMN2PRMT5 | |
| SCHEMBL4140258 | 0.84 | CCR1 (0.41) | HRH3CYP1A2CYP2D6KDM4ENPC1 | |
| SCHEMBL30398570 | 0.84 | HRH3 (0.55) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL487617 | 0.84 | HRH3 (0.55) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL5109146 | 0.83 | HRH3 (0.44) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL2380517 | 0.83 | HRH3 (0.50) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL5737703 | 0.80 | HRH3 (0.43) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL23199281 | 0.78 | CCR1 (0.37) | HRH3CYP1A2CYP2D6KDM4ENPC1 | |
| SCHEMBL16682705 | 0.78 | RECQL (0.36) | HRH3CYP1A2CYP2D6KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-26 | — | — | US | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2640722-B1 | PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-9115136-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| US-8921379-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| CN-102369205-B | fused ring compound and use thereof | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| CN-103788097-A | Fused ring compound and application thereof | TAKEDA PHARMACEUTICAL | 2014-05-14 | — | — | CN | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| CN-1321996-C | Process for producing 2-iminopyrrolidine derivative | SANITATION STUFF R & D MANAGE (JP) | 2007-06-20 | — | — | CN | disclosed |
| CN-1754880-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-04-05 | — | — | CN | disclosed |
| CN-1243735-C | 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-03-01 | — | — | CN | disclosed |
| CN-1733725-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| CN-1503784-A | 2-iminopyrrolidine derivatives | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | HRH3 3139/4885CYP1A2 34/4885CYP2D6 22/4885 |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | HRH3 8/4885CYP1A2 137/4885CYP2D6 138/4885 |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | HRH3 559/4885CYP1A2 38/4885CYP2D6 68/4885 |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | HRH3 287/4885CYP1A2 1393/4885CYP2D6 2640/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | HRH3 8/4885CYP1A2 136/4885CYP2D6 135/4885 |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | XDH, CYP2B6, COX6B1 | HRH3 572/4885CYP1A2 49/4885CYP2D6 4/4885 |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | TYK2, IFNG, IFNAR1 | HRH3 466/4885CYP1A2 784/4885CYP2D6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.